Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 6Neoplasms 5Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Vomiting 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nausea 1NSCLC 1Mucositis 1Mastocytosis, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

Carboplatin 7Pemetrexed 6osimertinib 5Drug Therapy 5aflutinib 4tislelizumab 3anlotinib 3Radiotherapy 3Radiosurgery 3Paclitaxel 3Cisplatin 3toripalimab 2pembrolizumab 2camrelizumab 2apatinib 2Surgical Procedures, Operative 2S 1 (combination) 2HM781-36B 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2trilaciclib 1surufatinib 1sintilimab 1rezivertinib 1lenvatinib 1icotinib 1famitinib 1envafolimab 1dacomitinib 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NSCLC × Diphenhydramine × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡